Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.59 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.59 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.59 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | PYGB | P11216 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446587 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL5444302 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL5444372 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL15370355 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL24115372 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL24243426 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL5444368 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL18537039 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL18383814 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL13197779 | 1.00 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 985 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410276-B2 | Method of recycling polyurethane materials | CARPENTER ENGINEERED FOAMS BELGIUM BV (BE) | 2025-09-09 | — | — | US | claimed |
| EP-4010414-B1 | IMPROVED METHOD OF RECYCLING POLYURETHANE MATERIALS | CARPENTER ENG FOAMS BELGIUM BV (BE) | 2025-06-18 | — | — | EP | claimed |
| US-20250161338-A1 | Compounds for Anti-aging Intervention | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-05-22 | — | — | US | claimed |
| US-20250073321-A1 | Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders | UNIV NEW YORK (US) | 2025-03-06 | — | — | US | claimed |
| WO-2025001479-A1 | SECONDARY BATTERY ELECTROLYTE ADDITIVE AND PREPARATION METHOD THEREFOR | 深圳新宙邦科技股份有限公司 | 2025-01-02 | — | — | WO | claimed |
| EP-4479038-A2 | COMPOUNDS FOR ANTI-AGING INTERVENTION | Agency for Science, Technology and Research (SG) | 2024-12-25 | — | — | EP | claimed |
| WO-2023158382-A2 | COMPOUNDS FOR ANTI-AGING INTERVENTION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-08-24 | — | — | WO | claimed |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | claimed |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | claimed |
| US-20230124589-A1 | Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis | DOUBLERAINBOW BIOSCIENCES INC. | 2023-04-20 | — | — | US | claimed |
| EP-0037319-B1 | MUCOPOLYSACCHARIDES HAVING BIOLOGICAL PROPERTIES; THEIR PREPARATION AND USE AS MEDICINES | D.R.O.P.I.C. (Société Civile) (FR) | 1987-04-08 | — | — | EP | claimed |
| EP-0214879-A2 | Process for sulfating glycosaminoglycanes, glycosaminoglycanes obtained and their biological applications | SANOFI (FR) | 1987-03-18 | — | — | EP | claimed |
| EP-0208623-A2 | Use of poly- and oligosaccharides for obtaining medicaments active in the pathologies of the connective tissue | SANOFI (FR) | 1987-01-14 | — | — | EP | claimed |
| EP-0076279-B1 | METHOD FOR OBTAINING BIOLOGICALLY ACTIVE MUCOPOLYSACCHARIDES OF HIGH PURITY BY CONTROLLED DEPOLYMERIZATION OF HEPARIN | CHOAY S.A. (FR) | 1986-09-17 | — | — | EP | claimed |
| EP-0181252-A1 | Process for preparing compositions of mucopolysaccharides having a high antithrombotic activity | CHOAY S.A. (FR) | 1986-05-14 | — | — | EP | claimed |
| EP-0163582-A2 | Medicines which improve the free-flowing properties of blood, and their therapeutical use | CHOAY S.A. (FR) | 1985-12-04 | — | — | EP | claimed |
| EP-0140781-A2 | Compositions containing heparin derivatives, especially useful in the treatment of disturbances by cell proliferation | DROPIC Société Civile de Gestion de Droit de Propriété Industrielle CHOAY (FR) | 1985-05-08 | — | — | EP | claimed |
| US-4500519-A | DEPOLYMERIZATION OF HEPARIN WITH NITOUS ACID-USEFUL FOR CONTROLLING THROMBOSIS | CHOAY S.A. (FR) | 1985-02-19 | — | — | US | claimed |
| EP-0037319-A1 | Mucopolysaccharides having biological properties; their preparation and use as medicines | D.R.O.P.I.C. (Société Civile) (FR) | 1981-10-07 | — | — | EP | claimed |
| WO-1981002737-A1 | MUCOPOLYSACCHARIDES HAVING BIOLOGICAL PROPERTIES,PREPARATION AND APPLICATION THEREOF AS DRUGS | CHOAY SA (FR) | 1981-10-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161338-A1 | Compounds for Anti-aging Intervention | GLA, SIRT1, TFAM | LGALS1 292/4885LGALS3 585/4885LGALS9 1271/4885 |
| US-20230124589-A1 | Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis | UGGT1, UGDH, GALE | LGALS1 402/4885LGALS3 383/4885LGALS9 611/4885 |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | UGDH, IDH1, G6PD | LGALS1 435/4885LGALS3 493/4885LGALS9 774/4885 |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | GALE, UGGT1, DERA | LGALS1 396/4885LGALS3 346/4885LGALS9 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.